Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $6.1 million.

  • Mirum Pharmaceuticals' Depreciation & Amortization (CF) rose 11.56% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year increase of 502.45%. This contributed to the annual value of $23.6 million for FY2024, which is 11820.11% up from last year.
  • As of Q3 2025, Mirum Pharmaceuticals' Depreciation & Amortization (CF) stood at $6.1 million, which was up 11.56% from $6.1 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Depreciation & Amortization (CF) registered a high of $6.1 million during Q3 2025, and its lowest value of $79000.0 during Q2 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $1.3 million (2023), whereas its average is $3.0 million.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Depreciation & Amortization (CF) soared by 120476.19% in 2022, and later increased by 11.56% in 2025.
  • Quarter analysis of 5 years shows Mirum Pharmaceuticals' Depreciation & Amortization (CF) stood at $342000.0 in 2021, then surged by 251.17% to $1.2 million in 2022, then skyrocketed by 357.45% to $5.5 million in 2023, then increased by 10.23% to $6.1 million in 2024, then increased by 0.1% to $6.1 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $6.1 million for Q3 2025, versus $6.1 million for Q2 2025 and $6.1 million for Q1 2025.